About Us

Founded in 2019 by the scientific pioneers who started the fields of Cardiac Gene Therapy over three decades ago at the Massachusetts General Hospital, Sardocor is a fully owned subsidiary of the Medera Group.


Sardocor is dedicated to the clinical development of novel therapies for patients with incurable diseases. With three ongoing gene therapy clinical trials for Heart Failure with preserved Ejection Fraction (HFpEF), Heart Failure with reduced Ejection Fraction (HFrEF) and Duchenne Muscular Dystrophy-associated Cardiomyopathy (DMD-CM), Sardocor is currently second to none in terms of the number of FDA Investigational New Drug (IND) approvals and the clinical stage maturity.

Cardiac gene therapy research

Management Team

Every member of our team is a thought leader who has made significant contributions to our society. 

Each one brings a unique set of skills and expertise to our organization. 

 

Ronald Li, PhD.

Chief Executive Officer

 

Roger Hajjar, PhD.

President and Chief Medical Officer

 

Jeff Rudy

Chief Operations Officer

 

Sue Kim, MBA

Financial Controller

 

Suresh Pullela 

Vice President, Quality Operations

 

Mary  Liberio

Senior Director of Manufacturing

 

Lijing Li

Global Head of Technical Operations

 

Scientific Advisory Board

Barry Borlaug, MD

Michael Taylor, MD, PhD

Pat Furlong, MS, BSN

Brian Jaski, MD

Dr. Hesham Sadek 

Dr. Pradeep Mammen

Dongsheng Duan, PhD

Share by: